---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-23-000028"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:17:05.369726+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Keros Q1 net loss $35.8M, cash $351.4M; KER-012 Phase 2 starts H1 2023

## Summary
- Net loss of $35.8M vs $24.2M in Q1 2022; R&D spend $31.1M (+$13.0M YoY) driving pipeline.
- Cash and equivalents $351.4M as of March 31, 2023; runway into Q4 2025.
- Dr. Alpna Seth appointed to board of directors in May 2023.
- KER-012 Phase 2 trial for pulmonary arterial hypertension planned to start H1 2023.
- KER-050 Phase 2 data readouts in MDS and myelofibrosis expected later this year.

## SEC filing metadata
- accession: 0001664710-23-000028
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000028/0001664710-23-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000028/kros-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-23-000028
- JSON: https://secwatch.observer/filing/0001664710-23-000028.json
- Plain text: https://secwatch.observer/filing/0001664710-23-000028.txt

## Key facts
- Earnings Releases
  Keros Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income net loss of $35.8 million.
  - Period: the quarter ended March 31, 2023
  - Net income: net loss of $35.8 million
  - Result: reported results
  source text: Keros reported a net loss of $35.8 million in the first quarter of 2023 as compared to a net loss of $24.2 million in the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000028/0001664710-23-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.